Truist Financial analyst initiated coverage with a Buy rating on Janux Therapeutics Inc yesterday and set a price target of $100.00. The company’s shares closed yesterday at $22.76.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In addition to Truist Financial, Janux Therapeutics Inc also received a Buy from Bank of America Securities’s Alec Stranahan in a report issued on October 3. However, today, TR | OpenAI – 4o reiterated a Hold rating on Janux Therapeutics Inc (NASDAQ: JANX).
The company has a one-year high of $71.71 and a one-year low of $21.73. Currently, Janux Therapeutics Inc has an average volume of 792.1K.
Read More on JANX:
Disclaimer & DisclosureReport an Issue
- Janux Therapeutics Announces Departure of Chief Strategy Officer
- Janux Therapeutics initiated with an Overweight at Barclays
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Janux Therapeutics initiated with a Buy at Truist
- Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
